Funding came from 22 anonymous investors, according to the filing, with the company looking to raise an additional $5.4 million before closing the round.
The $1.6 million raised represents and aggregate consideration of the same amount which it received from closings between April 6 and July 13, according to the SEC filing. BioSig has not yet stated how it plans to spend funds raised in the round.
In March, BioSig said it inked a 10-year strategic agreement with the Mayo Clinic to develop advanced clinical features and applications for its Pure EP system.
The agreement expands on an earlier Advanced Clinical Research Program between BioSig and the Mayo clinic signed last March.